James Gilligan
President chez TRYPTAMINE THERAPEUTICS LIMITED
Relations actives
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Agnes Olszewski | M | 67 | 22 ans | |
| James Kuo | M | 58 | 5 ans | |
| Peter Molloy | M | 52 | 4 ans | |
| Philip Jull | M | 64 | 4 ans | |
| Sidney Taubenfeld | M | - | 2 ans | |
| David S. Krause | M | - |
Tarsa Therapeutics, Inc.
 Tarsa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tarsa Therapeutics, Inc. engages in the development of therapies for the treatment and prevention of osteoporosis and related bone diseases. Its product OSTORA, is an oral formulation of calcitonin, which is a recombinant peptide hormone that inhibits bone resorption. The company was founded by David Brand and James Gilligan in 2009 and is headquartered in Philadelphia, PA. | 14 ans |
| Michael Silverman | M | - | - | |
| Christopher Ntoumenopoulos | M | - | 2 ans | |
| Peter Guzzo | M | - | 4 ans | |
| James O’Neill | M | 64 | 2 ans | |
| Jason Carroll | M | - | 1 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Garner William | M | 58 | 3 ans | |
| Gregory M. McKee | M | 60 | 1 ans | |
| Dave Tousley | M | 69 | 1 ans | |
| Don Soland | M | 65 |
Tarsa Therapeutics, Inc.
Tarsa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tarsa Therapeutics, Inc. engages in the development of therapies for the treatment and prevention of osteoporosis and related bone diseases. Its product OSTORA, is an oral formulation of calcitonin, which is a recombinant peptide hormone that inhibits bone resorption. The company was founded by David Brand and James Gilligan in 2009 and is headquartered in Philadelphia, PA. | - |
| George R. Maurer | M | 68 |
Tarsa Therapeutics, Inc.
Tarsa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tarsa Therapeutics, Inc. engages in the development of therapies for the treatment and prevention of osteoporosis and related bone diseases. Its product OSTORA, is an oral formulation of calcitonin, which is a recombinant peptide hormone that inhibits bone resorption. The company was founded by David Brand and James Gilligan in 2009 and is headquartered in Philadelphia, PA. | 5 ans |
| Nicholas LaBella | M | 68 |
Tarsa Therapeutics, Inc.
Tarsa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tarsa Therapeutics, Inc. engages in the development of therapies for the treatment and prevention of osteoporosis and related bone diseases. Its product OSTORA, is an oral formulation of calcitonin, which is a recombinant peptide hormone that inhibits bone resorption. The company was founded by David Brand and James Gilligan in 2009 and is headquartered in Philadelphia, PA. | 3 ans |
| Terese Gieselman | F | 62 | 1 ans | |
| Thomas D'Orazio | M | - | - | |
| Luke Hayes | M | - | - | |
| Lawrence Woo | M | - | - | |
| Joy Willis | F | - | 1 ans |
Statistiques
| Pays | Relations | % du total |
|---|---|---|
| Canada | 16 | 72,73% |
| Etats-Unis | 6 | 27,27% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- James Gilligan
- Réseau Personnel
